DIRECTORIO DE BUFETES en la WEB: A | B | C | D | E | F | G | H | I-K | L | M | N | O | P | Q | R | S | T | U | V | W-Z |
Le enviamos regularmente las últimas noticias
Su Nombre:
Su Email:
INTERNATIONAL DEALS
The joint venture is part of Teva's ongoing strategic expansion into the area of biosimilars, which are generic versions of biotechnology products. The joint venture is in the vanguard of the larger generic pharmaceutical companies' move into the area of biologics. "We are delighted to have had the opportunity to work with Teva on this strategic joint venture," says Corporate partner Jeremy Cohen, who led the Denton Wilde Sapte team. Teva, which is based in Israel, is the world's largest generic pharmaceutical company. Lonza is based in Switzerland and is the global leader in the manufacture and development of biopharmaceuticals. "The firm's Life Sciences and Intellectual Property practices have gone from strength to strength over recent years and we have a team of specialist lawyers with backgrounds in industry and academia. Our life sciences litigation and transactional practices have also developed significantly over this period," says TMT sector head Scott Singer, who advised on intellectual property aspects of the deal. Jeremy was assisted by Corporate senior associate Jemma Shorten, whilst Scott worked with TMT partner and life sciences specialists on the intellectual property, biotechnology and licensing aspects of the agreement. They were assisted by TMT associates Shauneen Kelly and Amarjit Purewal. Lonza were represented by Morgan Lewis partner Anthony Warnock-Smith and associate Fiana McGuinness.
copyright, 2006 - Strong Element, S.L. - Peña Sacra 18 - E-28260 Galapagar - Madrid - Spain - Tel.: + 34 91 858 75 55 - Fax: + 34 91 858 56 97 - info@lawyerpress.com - www.lawyerpress.com - Aviso legal
